TG Therapeutics, Inc. is preparing for its first commercial launch now that the US Food and Drug Administration has approved Ukoniq (umbralisib) for two forms of lymphoma. Another submission is under way for a combination of umbralisib with TG’s glycoengineered anti-CD20 monoclonal antibody ublituximab, which means the company is poised to soon be a multi-asset cancer company.
FDA granted an accelerated approval to the first-in-class phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon inhibitor on 5 February, marking an important milestone for TG Therapeutics